300255 常山药业
已收盘 09-30 15:00:00
资讯
新帖
简况
常山药业(300255)9月29日主力资金净卖出1957.14万元
证券之星 · 09-30
常山药业(300255)9月29日主力资金净卖出1957.14万元
常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料
证券之星 · 09-24
常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料
股市必读:常山药业新发布《关于全资子公司为公司提供担保的进展公告》
证券之星 · 09-23
股市必读:常山药业新发布《关于全资子公司为公司提供担保的进展公告》
常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作
证券之星 · 09-22
常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作
常山药业(300255)9月18日股东户数6.15万户,较上期减少0.58%
证券之星 · 09-21
常山药业(300255)9月18日股东户数6.15万户,较上期减少0.58%
常山药业:截至2026年9月18日,公司的股东户数为61456户
证券之星 · 09-21
常山药业:截至2026年9月18日,公司的股东户数为61456户
常山药业(300255)9月10日股东户数6.18万户,较上期减少2.58%
证券之星 · 09-16
常山药业(300255)9月10日股东户数6.18万户,较上期减少2.58%
常山药业(300255.SZ):肝素钠注射液获得摩尔多瓦药品注册证书
智通财经 · 09-15
常山药业(300255.SZ):肝素钠注射液获得摩尔多瓦药品注册证书
常山药业(300255)披露控股股东股票质押及解除质押公告,9月14日股价上涨0.49%
证券之星 · 09-14
常山药业(300255)披露控股股东股票质押及解除质押公告,9月14日股价上涨0.49%
股市必读:常山药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
证券之星 · 09-14
股市必读:常山药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
常山药业(300255)股东高树华质押500万股,占总股本0.54%
证券之星 · 09-12
常山药业(300255)股东高树华质押500万股,占总股本0.54%
常山药业(300255)披露将参加河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会,9月10日股价下跌1.25%
证券之星 · 09-10
常山药业(300255)披露将参加河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会,9月10日股价下跌1.25%
股市必读:常山药业新发布《第六届董事会第九次会议决议公告》
证券之星 · 09-09
股市必读:常山药业新发布《第六届董事会第九次会议决议公告》
常山药业:艾本那肽减重适应症Ⅰ期临床试验尚未完成首例受试者入组
证券之星 · 09-03
常山药业:艾本那肽减重适应症Ⅰ期临床试验尚未完成首例受试者入组
常山药业(300255)8月31日股东户数6.34万户,较上期减少5.48%
证券之星 · 09-03
常山药业(300255)8月31日股东户数6.34万户,较上期减少5.48%
常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作
证券之星 · 09-03
常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作
常山药业:截至2026年8月31日,公司的股东户数为63447户
证券之星 · 09-03
常山药业:截至2026年8月31日,公司的股东户数为63447户
常山药业(300255.SZ)发布上半年业绩,归母净亏损1676.18万元
智通财经网 · 08-25
常山药业(300255.SZ)发布上半年业绩,归母净亏损1676.18万元
常山药业(300255)披露2026年半年度报告及其摘要,8月25日股价上涨3.04%
证券之星 · 08-25
常山药业(300255)披露2026年半年度报告及其摘要,8月25日股价上涨3.04%
图解常山药业中报:第二季度单季净利润同比增长31.15%
证券之星 · 08-25
图解常山药业中报:第二季度单季净利润同比增长31.15%
加载更多
公司概况
公司名称:
河北常山生化药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。
发行价格:
28.00
{"stockData":{"symbol":"300255","market":"SZ","secType":"STK","nameCN":"常山药业","latestPrice":22.94,"timestamp":1790751837000,"preClose":22.12,"halted":0,"volume":25463124,"delay":0,"changeRate":0.0371,"floatShares":918000000,"shares":919000000,"eps":-0.3761,"marketStatus":"已收盘","change":0.82,"latestTime":"09-30 15:00:00","open":22.5,"high":23.29,"low":22.27,"amount":584000000,"amplitude":0.0461,"askPrice":22.94,"askSize":346,"bidPrice":22.93,"bidSize":150,"shortable":0,"etf":0,"ttmEps":-0.3761,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":22.12,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":24.33,"lowLimit":19.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":919060878,"isCdr":false,"pbRate":17.12,"roa":"--","roe":"--","epsLYR":-0.39,"committee":0.184192,"marketValue":21083000000,"turnoverRate":0.0277,"status":0,"floatMarketCap":21052000000},"requestUrl":"/m/hq/s/300255","defaultTab":"news","newsList":[{"id":"2671226054","title":"常山药业(300255)9月29日主力资金净卖出1957.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671226054?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:17","pubTimestamp":1790731046,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月29日收盘,常山药业报收于22.12元,下跌1.51%,换手率1.94%,成交量17.82万手,成交额4.0亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入1988.2万元,融资偿还3249.74万元,融资净偿还1261.54万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000007824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669043745","title":"常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2669043745","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669043745?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:42","pubTimestamp":1790210536,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,请问公司收到阿贝那肽二次发布的具体时间?资料提交的具体截止时间是9月30日吗?常山药业回复:尊敬的投资者,您好。公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料。艾本那肽上市审评后续流程环节仍然较多、审评周期较长,最终审评结果及完成审评时间均存在不确定性。请投资者高度关注上述风险,慎重决策。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400008078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669218441","title":"股市必读:常山药业新发布《关于全资子公司为公司提供担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669218441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669218441?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:16","pubTimestamp":1790100972,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘,常山药业报收于23.99元,下跌0.46%,换手率2.31%,成交量21.23万手,成交额5.09亿元。公司公告汇总:全资子公司常山生化药业(江苏)有限公司为母公司提供不超过7亿元本金及利息的连带责任保证,截至公告日公司及控股子公司实际担保余额12.16亿元,占最近一期经审计净资产的100.98%。本次担保在已审批的年度担保额度范围内,无需另行审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511173","title":"常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669511173?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:21","pubTimestamp":1790061665,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问:你好董秘董高官,这次发补还会压着最后提交日期提交吗常山药业回复:尊敬的投资者,您好!公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作,相关资料正在有序、完善筹备中,目前尚未完成上述工作。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200020912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669479154","title":"常山药业(300255)9月18日股东户数6.15万户,较上期减少0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669479154","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669479154?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:42","pubTimestamp":1789983720,"startTime":"0","endTime":"0","summary":"证券之星消息,近日常山药业披露,截至2026年9月18日公司股东户数为6.15万户,较9月10日减少357.0户,减幅为0.58%。在化学制药行业个股中,常山药业股东户数高于行业平均水平,截至9月18日,化学制药行业平均股东户数为3.64万户。从股价来看,2026年9月10日至2026年9月18日,常山药业区间涨幅为1.05%,在此期间股东户数减少357.0户,减幅为0.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100022725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115618","title":"常山药业:截至2026年9月18日,公司的股东户数为61456户","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115618","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669115618?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:18","pubTimestamp":1789978690,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,请告知公司9月20日的股东人数是多少,谢谢!常山药业回复:尊敬的投资者,您好!截至2026年9月18日,公司的股东户数为61456户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100019068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0172","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667260122","title":"常山药业(300255)9月10日股东户数6.18万户,较上期减少2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667260122","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667260122?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:38","pubTimestamp":1789551506,"startTime":"0","endTime":"0","summary":"证券之星消息,近日常山药业披露,截至2026年9月10日公司股东户数为6.18万户,较8月31日减少1634.0户,减幅为2.58%。在化学制药行业个股中,常山药业股东户数高于行业平均水平,截至9月10日,化学制药行业平均股东户数为3.64万户。从股价来看,2026年8月31日至2026年9月10日,常山药业区间跌幅为3.51%,在此期间股东户数减少1634.0户,减幅为2.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600027909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617303","title":"常山药业(300255.SZ):肝素钠注射液获得摩尔多瓦药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617303","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617303?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:51","pubTimestamp":1789458686,"startTime":"0","endTime":"0","summary":"智通财经APP讯,常山药业(300255.SZ)发布公告,公司于近日收到通知,公司药品肝素钠注射液获得摩尔多瓦药品监督管理部门签发的药品注册证书。肝素钠注射液主要用于防治血栓形成或栓塞性疾病(如心肌梗塞、血栓性静脉炎、肺栓塞等);各种原因引起的弥漫性血管内凝血(DIC);也用于血液透析、体外循环、导管术、微血管手术等操作过程及某些血液标本或器械的抗凝处理。本次肝素钠注射液获得摩尔多瓦注册批文,对公司拓展海外市场带来一定积极影响。目前公司肝素制剂产品海外销售收入占公司营业总收入比例较低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300255","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654708","title":"常山药业(300255)披露控股股东股票质押及解除质押公告,9月14日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654708","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654708?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:37","pubTimestamp":1789378654,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘,常山药业报收于22.61元,较前一交易日上涨0.49%,最新总市值为207.8亿元。公告显示,公司控股股东高树华先生近期进行了股份质押及解除质押操作。本次合计质押股份48,000,000股,占其所持股份比例17.10%,占公司总股本比例5.22%;合计解除质押股份34,700,000股,占其所持股份比例12.36%,占公司总股本比例3.78%。截至公告披露日,高树华累计质押股份179,206,400股,占其所持股份比例63.86%,占公司总股本比例19.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680979","title":"股市必读:常山药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680979?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:00","pubTimestamp":1789322445,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,常山药业报收于22.5元,下跌1.4%,换手率1.51%,成交量13.88万手,成交额3.14亿元。公司公告汇总:公司将于9月16日15:30–17:00参加河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会。公司公告汇总:控股股东高树华新增质押股份48,000,000股,占公司总股本5.22%;同时解除质押34,700,000股,占公司总股本3.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666576543","title":"常山药业(300255)股东高树华质押500万股,占总股本0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666576543?lang=zh_cn&edition=full","pubTime":"2026-09-12 00:18","pubTimestamp":1789143507,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业9月12日公开信息显示,股东高树华向**银行股份有限公司北京分行合计质押500.0万股,占总股本0.54%。质押详情见下表:截止本公告日,股东高树华已累计质押股份1.79亿股,占其持股总数的63.86%。本文数据来源于常山药业公告,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091200000649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0070","BK0172","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666913295","title":"常山药业(300255)披露将参加河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会,9月10日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666913295","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666913295?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:10","pubTimestamp":1789049427,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,常山药业报收于22.82元,较前一交易日下跌1.25%,最新总市值为209.73亿元。该股当日开盘22.92元,最高22.94元,最低22.33元,成交额达3.48亿元,换手率为1.68%。近日,常山药业披露《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》。公告显示,公司将于2026年9月16日15:30-17:00通过网络远程方式参加由河北上市公司协会、河北资本市场之家与深圳市全景网络有限公司联合举办的本次活动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000041903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666744583","title":"股市必读:常山药业新发布《第六届董事会第九次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666744583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666744583?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:00","pubTimestamp":1788886843,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第九次会议决议公告河北常山生化药业股份有限公司于2026年9月7日以通讯方式召开第六届董事会第九次会议,应出席董事6名,实际出席6名,由董事长高晓东主持。董事会已审议通过授权副总经理常颜路代行总经理职责,期限自审议通过之日起至新任总经理聘任之日止;常颜路未持有公司股份,具备任职资格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300255","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872344","title":"常山药业:艾本那肽减重适应症Ⅰ期临床试验尚未完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664872344?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:48","pubTimestamp":1788439686,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,为什么阿贝那肽减重一期还不开始启动入组,拿到临床批件已经一年多了,进度为什么这么慢呢?常山药业回复:尊敬的投资者,您好!公司艾本那肽用于减重适应症的Ⅰ期临床试验,相关工作正在有序筹备中,尚未完成首例受试者入组。公司始终稳步推进相关临床试验,后续如取得重大研发进展,公司将严格按照监管规则及时履行信息披露义务。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300039678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873872","title":"常山药业(300255)8月31日股东户数6.34万户,较上期减少5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873872","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664873872?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:35","pubTimestamp":1788428129,"startTime":"0","endTime":"0","summary":"证券之星消息,近日常山药业披露,截至2026年8月31日公司股东户数为6.34万户,较8月20日减少3675.0户,减幅为5.48%。在化学制药行业个股中,常山药业股东户数高于行业平均水平,截至8月31日,化学制药行业平均股东户数为3.66万户。从股价来看,2026年8月20日至2026年8月31日,常山药业区间跌幅为7.44%,在此期间股东户数减少3675.0户,减幅为5.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300031821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664284770","title":"常山药业:公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664284770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664284770?lang=zh_cn&edition=full","pubTime":"2026-09-03 08:42","pubTimestamp":1788396131,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,阿贝那肽二次技术发补,截止今天:2026年8月26日还剩26个工作日,按照此推算,最迟提交发补资料时限是10月9日。请问目前公司资料准备情况,为何还没提交发补资料,预计还需要多久?常山药业回复:尊敬的投资者,您好!公司正在根据审评要求积极稳步推进艾本那肽(阿贝那肽)的补充资料相关工作,相关资料正在有序、完善筹备中,目前尚未完成上述工作。后续相关重大进展请您关注公司将来披露的官方公告。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300007792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0070","BK0172","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664384770","title":"常山药业:截至2026年8月31日,公司的股东户数为63447户","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664384770?lang=zh_cn&edition=full","pubTime":"2026-09-03 08:39","pubTimestamp":1788395954,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,请问截止8月31日的股东人数?常山药业回复:尊敬的投资者,您好!截至2026年8月31日,公司的股东户数为63447户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300007774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731788","title":"常山药业(300255.SZ)发布上半年业绩,归母净亏损1676.18万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731788","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662731788?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:56","pubTimestamp":1787659001,"startTime":"0","endTime":"0","summary":"智通财经APP讯,常山药业 发布2026年半年度报告,报告期内,公司实现营业收入4.76亿元,同比下降3.21%。归属于上市公司股东净亏损1676.18万元,归属于上市公司股东的扣除非经常性损益净亏损2186.1万元。2026年上半年,公司肝素制剂产品整体销量为3,098.45万支,较上年同期增长35.89%;销售收入为27,378.78万元,同比增长17.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"常山药业(300255.SZ)发布上半年业绩,归母净亏损1676.18万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736462","title":"常山药业(300255)披露2026年半年度报告及其摘要,8月25日股价上涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736462","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736462?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655469,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,常山药业报收于24.09元,较前一交易日上涨3.04%,最新总市值为221.4亿元。该股当日开盘23.16元,最高24.21元,最低22.8元,成交额达6.36亿元,换手率为2.92%。近日,河北常山生化药业股份有限公司披露《第六届董事会第八次会议决议公告》。会议应出席董事6名,实际出席6名,表决结果均为6票同意,0票反对,0票弃权。公告指出,公司2026年半年度报告真实、准确、完整地反映了经营情况,财务报告已由董事会审计委员会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662735363","title":"图解常山药业中报:第二季度单季净利润同比增长31.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662735363","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662735363?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:19","pubTimestamp":1787653180,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业2026年中报显示,上半年度公司主营收入4.76亿元,同比下降3.21%;归母净利润-1676.18万元,同比上升42.38%;扣非净利润-2186.1万元,同比上升27.75%;其中2026年第二季度,公司单季度主营收入2.2亿元,同比下降5.66%;单季度归母净利润-2263.28万元,同比上升31.15%;单季度扣非净利润-2313.36万元,同比上升30.47%;负债率74.46%,财务费用4950.58万元,毛利率21.62%。财报数据概要请见下图:本文数据来源于常山药业2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500038903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791191936444,"stockEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.03},{"period":"3month","weight":-0.0705},{"period":"6month","weight":-0.4675},{"period":"1year","weight":-0.4964},{"period":"ytd","weight":-0.6306}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河北常山生化药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61456人(较上一季度减少0.58%)","perCapita":"14932股","listingDate":"2011-08-19","address":"河北省石家庄市正定县中国(河北)自由贸易试验区正定片区高新技术产业开发区南区梦龙街71号","registeredCapital":"91906万元","survey":" 河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"常山药业,300255,常山药业股票,常山药业股票老虎,常山药业股票老虎国际,常山药业行情,常山药业股票行情,常山药业股价,常山药业股市,常山药业股票价格,常山药业股票交易,常山药业股票购买,常山药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}